US › Healthcare

Scinai Immunotherapeutics Ltd (SCNI)

US · Healthcare · Biotechnology

$1.62+6.58%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$467,898

Revenue YoY

-20.2%

Net profit

$-2.0M

EPS

$-0.74

Net margin

-435.4%

Key statistics

Market cap

$1.0M

P/E

0.1

Forward P/E

0.0

P/B

0.17

Book value

$10.71

EPS (TTM)

$17.86

52-week high

$16.30

52-week low

$1.43

50-day MA

$2.45

200-day MA

$5.77

Beta

2.08

Analyst view

Analysts rate Scinai Immunotherapeutics Ltd a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $700.00.

Shareholding

Insiders

14.16%

Institutions

4.29%

Largest institutional holders

Fund	Stake
XTX Topco Ltd	0.61%
Rhumbline Advisers	0.05%
UBS Group AG	0.02%
Morgan Stanley - Brokerage Accounts	0.00%
Virtu Financial LLC	0.00%
Citadel Advisors Llc	0.00%
Northwestern Mutual Wealth Management Co	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Scinai Immunotherapeutics Ltd — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.